---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-072270"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:08:31.130837+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Acurx Pharmaceuticals announces results of annual shareholder meeting; directors elected, auditor ratified

## Summary
- Quorum of 67.29% of outstanding shares (10,648,350 of 15,823,102) was present at June 17, 2024 Annual Meeting.
- Class III directors Robert J. DeLuccia, Joseph C. Scodari, James Donohue re-elected with broker non-votes of 4,836,213 each.
- Ratification of CohnReznick LLP as independent auditor for FY2024 passed with 10,542,955 votes for, 69,261 against, 36,134 abstentions.
- All director nominees received majority of votes cast excluding broker non-votes.

## SEC filing metadata
- accession: 0001104659-24-072270
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465924072270/0001104659-24-072270-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465924072270/tm2417425d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-072270
- JSON: https://secwatch.observer/filing/0001104659-24-072270.json
- Plain text: https://secwatch.observer/filing/0001104659-24-072270.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.